Kisspeptin vs hCG: An Unapproved Trigger and an Approved Hormone
hCG is FDA-approved and dosed off its label for hypogonadism and fertility. Kisspeptin has real human data but no approval - FDA reviewed it in 2024.
The short version
Kisspeptin and hCG both sit on the reproductive hormone axis, at different points and with very different regulatory histories. The hormone hCG is a decades-old FDA-approved hormone with a label, doses and an indication. Kisspeptin is the hormone one step upstream of it. It has genuine but small human research behind it and no approved product. FDA reviewed kisspeptin-10 for compounding in 2024 and found the evidence too thin. Neither is a fertility or testosterone protocol to self-administer.
- hCG mimics LH directly on the gonads. Kisspeptin acts upstream, triggering the hypothalamus to release GnRH.
- hCG is FDA-approved, with a label, for cryptorchidism, male hypogonadotropic hypogonadism, and ovulation induction.
- No kisspeptin product is FDA-approved. FDA's 2024 review proposed against adding kisspeptin-10 to the compounding bulks list.
- Both are on the WADA 2026 Prohibited List under the same subsection, S2.2.1, as testosterone-stimulating peptides in males.
Both kisspeptin and hCG are marketed for low testosterone and fertility. They sit on the same reproductive hormone axis, but at different points on it. hCG has decades of FDA approval behind it. Kisspeptin has never been approved for anything.
Side by side
| Kisspeptin | hCG (chorionic gonadotropin) | |
|---|---|---|
| What it is | Hypothalamic peptide, the trigger hormone upstream of GnRH | Placental glycoprotein hormone that mimics LH |
| Where it acts | KISS1R on GnRH neurons in the hypothalamus | Directly on LH receptors in the testes or ovaries |
| Approved use | None | Cryptorchidism; male hypogonadotropic hypogonadism; ovulation induction |
| US approval | Never FDA-approved; 2024 review against compounding | FDA-approved (e.g. Novarel), decades-old |
| Route | Subcutaneous or IV, in published studies | Intramuscular injection, per label |
| Human dose | No approved dose; short study doses only | Label dose, varies by indication |
| Longest human study | 2 weeks (twice-daily, then tachyphylaxis set in) | Label regimens run 3 weeks to 9 months |
| WADA 2026 | S2.2.1, prohibited at all times (males) | S2.2.1, prohibited at all times (males) |
Full pages: Kisspeptin · hCG. Dosing detail: kisspeptin dosage · hCG dosage.
Different points on the same axis
hCG is a glycoprotein hormone, structurally similar to LH. It binds LH receptors directly on the testes or ovaries, substituting for the pituitary’s own LH signal. Kisspeptin does not touch that receptor. It binds KISS1R on GnRH-secreting neurons in the hypothalamus and triggers GnRH release. GnRH then drives the pituitary to secrete LH and FSH. hCG skips the upstream chain and acts at the end of it. Kisspeptin tries to restart the chain from its beginning.
That difference decides who each one could plausibly help. hCG works even if the hypothalamus and pituitary are not signalling properly, because it bypasses them. Kisspeptin only works if the pituitary can still respond to the GnRH pulse it triggers. It cannot substitute for a non-functioning pituitary or gonad the way hCG can.
Evidence: decades of clinical use versus short research studies
hCG’s evidence is its approval. It has been used clinically for decades for cryptorchidism, male hypogonadotropic hypogonadism and ovulation induction. Its FDA label rests on that record, and fertility clinics use it routinely today.
Consistent findings across large trials or meta-analyses. Long-standing FDA-approved product with a label built on decades of clinical use for cryptorchidism, male hypogonadotropic hypogonadism and ovulation induction. The rating describes those approved uses, not off-label testosterone or performance use.
Kisspeptin’s human research is real but small. Two trials stand out:
- Healthy men. Intravenous kisspeptin-10 was given as a bolus (0.01-3.0 micrograms/kg) and by infusion. The largest LH rise came at 1 microgram/kg, and the highest dose produced a smaller rise, not a larger one. George 2011 - George JT, Veldhuis JD, Roseweir AK et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab. 2011;96(8):E1228-36., in the references below
- Women with hypothalamic amenorrhea. Twice-daily subcutaneous kisspeptin-54 (6.4 nmol/kg) was given for two weeks. The LH and FSH response was strong after the first injection and had mostly disappeared by day 14. The authors attribute this to tachyphylaxis. Jayasena 2009 - Jayasena CN, Nijher GM, Chaudhri OB et al. Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis. J Clin Endocrinol Metab. 2009;94(11):4315-23., in the references below
Small or uncontrolled human studies. Too little to settle the question either way. Genuine, published, controlled human studies exist, but they are short - the longest repeated-dose trial ran two weeks and ended with a weakened hormone response. FDA's own 2024 review reached the same conclusion: real signal, insufficient evidence for a treatment claim.
Dosing, as each page states it
hCG has an FDA label with several regimens, depending on indication:
- Male hypogonadotropic hypogonadism: 500-1,000 USP units intramuscularly three times weekly for three weeks, then the same dose twice weekly for three weeks. The alternative is 4,000 USP units three times weekly for six to nine months.
- Ovulation induction: 5,000-10,000 USP units, one day after the last dose of menotropins.
- Cryptorchidism: several regimens exist, including 4,000 USP units three times weekly for three weeks.
Full detail: hCG dosage.
Kisspeptin has no approved dose. Published human studies used intravenous bolus doses of 0.01-3.0 micrograms/kg kisspeptin-10 in healthy men, with the largest LH response at 1 microgram/kg George 2011 - George JT, Veldhuis JD, Roseweir AK et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab. 2011;96(8):E1228-36., in the references below. They also used twice-daily subcutaneous kisspeptin-54 at 6.4 nmol/kg for two weeks in women with hypothalamic amenorrhea. That schedule had stopped working by day 14 Jayasena 2009 - Jayasena CN, Nijher GM, Chaudhri OB et al. Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis. J Clin Endocrinol Metab. 2009;94(11):4315-23., in the references below. These are research-unit figures from monitored studies, not a take-home protocol. Full detail: kisspeptin dosage.
Who should not use either, and the main risks
hCG’s label lists these contraindications: precocious puberty, prostatic carcinoma or other androgen-dependent neoplasm, and prior allergic reaction to hCG. Its warnings cover ovarian hyperstimulation, ovarian cyst enlargement or rupture, multiple births, arterial thromboembolism, and anaphylaxis with urinary-derived products.
Kisspeptin has no FDA-reviewed contraindication list, because it has never gone through that review for any consumer use. FDA’s 2024 evaluation found kisspeptin-10 “is not well characterized from the physical and chemical characterization perspective” and flagged a potential immunogenicity risk for injectable use. The tachyphylaxis finding above also means a repeated dosing schedule can stop working rather than build an effect over time Jayasena 2009 - Jayasena CN, Nijher GM, Chaudhri OB et al. Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis. J Clin Endocrinol Metab. 2009;94(11):4315-23., in the references below. Material sold as a research chemical carries no regulator-verified purity, identity or concentration.
Regulatory status
hCG
US legal status - FDA-approved · prescription only
FDA-approved chorionic gonadotropin products (e.g. Novarel) exist for prepubertal cryptorchidism, selected male hypogonadotropic hypogonadism, and ovulation induction. Requires a prescriber; the label's regimens do not cover off-label testosterone or performance use.
Kisspeptin
US legal status - Research use only
No kisspeptin product is FDA-approved. FDA's October 2024 briefing document proposed not adding kisspeptin-10 to the 503A Bulks List, so it is not presently eligible for lawful 503A compounding for the use FDA evaluated.
Sport
Both sit in the same WADA 2026 subsection, S2.2.1, testosterone-stimulating peptides in males. Chorionic gonadotrophin (CG) and kisspeptin and its agonist analogues are named together, alongside LH and GnRH-releasing analogues. All are prohibited at all times, in and out of competition. A prescription for hCG does not change that status for a male athlete.
What the comparison tells you
Only hCG finished the approval process. It has a label, dose regimens and decades of clinical use behind a defined set of indications. Kisspeptin has genuine published human data showing it raises LH and FSH. FDA looked at that same evidence in 2024 and found it too thin to support a compounding use, let alone unsupervised repeated dosing. Being upstream of hCG on the same axis does not make kisspeptin a substitute for it.
Related
Common questions
Is kisspeptin the same as hCG?
No. hCG mimics luteinizing hormone and acts directly on the gonads, the testes or ovaries. Kisspeptin acts one step earlier, on the hypothalamus, triggering the release of GnRH. GnRH then prompts the pituitary to release LH and FSH. They sit on the same axis but act at different points in it.
Is hCG FDA-approved?
Yes. Chorionic gonadotropin products such as Novarel are FDA-approved, with a current label on DailyMed. The approved uses are prepubertal cryptorchidism, selected cases of hypogonadotropic hypogonadism in males, and induction of ovulation in anovulatory infertile women pretreated with menotropins.
Is kisspeptin FDA-approved?
No. FDA has not approved any kisspeptin or kisspeptin-analogue product for any indication. In an October 2024 briefing document, FDA proposed not adding kisspeptin-10 to the list of substances pharmacies may lawfully compound. It cited gaps in characterisation, immunogenicity and effectiveness.
Which is better for raising testosterone, kisspeptin or hCG?
hCG has decades of clinical use and an approved indication for male hypogonadotropic hypogonadism, with a label dose. Kisspeptin has short human studies showing it raises LH and FSH, but no trial has tested it as a repeated take-home therapy. FDA's 2024 review found the evidence too thin to support a compounding use for low testosterone in men.
References (5 sources)
Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.
- 1.Jayasena CN, Nijher GM, Chaudhri OB et al. Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis. J Clin Endocrinol Metab. 2009;94(11):4315-23.Randomised trialPMID 19820030
- 2.George JT, Veldhuis JD, Roseweir AK et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab. 2011;96(8):E1228-36.Clinical trialPMID 21632807full text
- 3.NOVAREL (chorionic gonadotropin) - current FDA prescribing information on DailyMed: dosage for cryptorchidism, hypogonadotropic hypogonadism and ovulation induction, contraindications and warnings.- DailyMed, National Library of Medicinelabel
- 4.FDA Briefing Document, Pharmacy Compounding Advisory Committee, 29 October 2024 - full evaluation of kisspeptin-10, including the proposal not to add it to the 503A Bulks List.- US Food and Drug Administrationregulatory
- 5.JADCO 2026 Prohibited List (WADA mirror, PDF) - section S2.2.1, testosterone-stimulating peptides in males, naming chorionic gonadotrophin (CG) and kisspeptin and its agonist analogues together, prohibited at all times.- World Anti-Doping Agency (mirrored by the Jamaica Anti-Doping Commission)regulatory